Trial Profile
Effects of KDT501 on Metabolic Features in Insulin Resistant Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs AMTX 036 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors KinDex Pharmaceuticals
- 28 Dec 2015 According to ClinicalTrials.gov record, status changed from recruiting to completed.
- 18 May 2015 New trial record